Total Payments
$443,059
2024 Payments
$5,986
Companies
7
Transactions
161
Payment Breakdown by Category
Consulting$348,475 (78.7%)
Royalty/License$63,118 (14.2%)
Travel$25,227 (5.7%)
Research$3,500 (0.8%)
Food & Beverage$2,739 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $348,475 | 23 | 78.7% |
| Royalty or License | $63,118 | 36 | 14.2% |
| Travel and Lodging | $25,227 | 66 | 5.7% |
| Unspecified | $3,500 | 2 | 0.8% |
| Food and Beverage | $2,739 | 34 | 0.6% |
Payments by Type
General
$439,559
159 transactions
Research
$3,500
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Helsinn Therapeutics (U.S.), Inc. | $275,678 | 90 | $0 (2023) |
| PFIZER INC. | $58,026 | 18 | $0 (2022) |
| Helsinn Healthcare SA | $36,474 | 27 | $0 (2024) |
| EMD Serono Research & Development Institute | $35,244 | 5 | $0 (2017) |
| EMD Serono, Inc. | $30,845 | 17 | $0 (2020) |
| Merck KGaA | $4,880 | 3 | $0 (2022) |
| Mannkind Corporation | $1,913 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $5,986 | 4 | Helsinn Healthcare SA ($5,986) |
| 2023 | $8,065 | 8 | Helsinn Healthcare SA ($5,682) |
| 2022 | $12,953 | 7 | Helsinn Healthcare SA ($5,110) |
| 2021 | $4,570 | 4 | Helsinn Healthcare SA ($4,570) |
| 2020 | $15,183 | 11 | Helsinn Healthcare SA ($14,374) |
| 2019 | $82,218 | 33 | Helsinn Therapeutics (U.S.), Inc. ($56,922) |
| 2018 | $150,788 | 48 | Helsinn Therapeutics (U.S.), Inc. ($109,185) |
| 2017 | $163,298 | 46 | Helsinn Therapeutics (U.S.), Inc. ($107,189) |
All Payment Transactions
161 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/15/2024 | Helsinn Healthcare SA | VALCHLOR (Drug) | Royalty or License | Cash or cash equivalent | $1,373.07 | General |
| Category: ONCOLOGY | ||||||
| 08/14/2024 | Helsinn Healthcare SA | VALCHLOR (Drug) | Royalty or License | Cash or cash equivalent | $1,565.61 | General |
| Category: ONCOLOGY | ||||||
| 05/14/2024 | Helsinn Healthcare SA | VALCHLOR (Drug) | Royalty or License | Cash or cash equivalent | $1,491.03 | General |
| Category: ONCOLOGY | ||||||
| 02/28/2024 | Helsinn Healthcare SA | VALCHLOR (Drug) | Royalty or License | Cash or cash equivalent | $1,556.15 | General |
| Category: ONCOLOGY | ||||||
| 11/15/2023 | Helsinn Healthcare SA | VALCHLOR (Drug) | Royalty or License | Cash or cash equivalent | $1,513.72 | General |
| Category: ONCOLOGY | ||||||
| 11/08/2023 | Helsinn Therapeutics (U.S.), Inc. | VALCHLOR (Drug) | Royalty or License | Cash or cash equivalent | $634.91 | General |
| Category: ONCOLOGY | ||||||
| 08/16/2023 | Helsinn Therapeutics (U.S.), Inc. | VALCHLOR (Drug) | Royalty or License | Cash or cash equivalent | $725.73 | General |
| Category: ONCOLOGY | ||||||
| 08/10/2023 | Helsinn Healthcare SA | VALCHLOR (Drug) | Royalty or License | Cash or cash equivalent | $1,730.25 | General |
| Category: ONCOLOGY | ||||||
| 05/17/2023 | Helsinn Therapeutics (U.S.), Inc. | VALCHLOR (Drug) | Royalty or License | Cash or cash equivalent | $601.32 | General |
| Category: ONCOLOGY | ||||||
| 05/10/2023 | Helsinn Healthcare SA | VALCHLOR (Drug) | Royalty or License | Cash or cash equivalent | $1,433.65 | General |
| Category: ONCOLOGY | ||||||
| 03/01/2023 | Helsinn Therapeutics (U.S.), Inc. | VALCHLOR (Drug) | Royalty or License | Cash or cash equivalent | $421.12 | General |
| Category: ONCOLOGY | ||||||
| 02/23/2023 | Helsinn Healthcare SA | VALCHLOR (Drug) | Royalty or License | Cash or cash equivalent | $1,004.02 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2022 | Helsinn Healthcare SA | VALCHLOR (Drug) | Royalty or License | Cash or cash equivalent | $1,281.37 | General |
| Category: ONCOLOGY | ||||||
| 10/08/2022 | Merck KGaA | Mavenclad (Drug) | Consulting Fee | Cash or cash equivalent | $1,380.00 | General |
| Category: Neurology | ||||||
| 10/07/2022 | Mannkind Corporation | AFREZZA (Drug) | Consulting Fee | Cash or cash equivalent | $1,912.50 | General |
| Category: DIABETES MEDICINE | ||||||
| 08/10/2022 | Helsinn Healthcare SA | VALCHLOR (Drug) | Royalty or License | Cash or cash equivalent | $1,325.42 | General |
| Category: ONCOLOGY | ||||||
| 06/06/2022 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $4,550.00 | General |
| 05/13/2022 | Helsinn Healthcare SA | VALCHLOR (Drug) | Royalty or License | Cash or cash equivalent | $1,317.10 | General |
| Category: ONCOLOGY | ||||||
| 02/14/2022 | Helsinn Healthcare SA | VALCHLOR (Drug) | Royalty or License | Cash or cash equivalent | $1,186.14 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2021 | Helsinn Healthcare SA | VALCHLOR (Drug) | Royalty or License | Cash or cash equivalent | $1,213.20 | General |
| Category: ONCOLOGY | ||||||
| 08/12/2021 | Helsinn Healthcare SA | VALCHLOR (Drug) | Royalty or License | Cash or cash equivalent | $1,185.26 | General |
| Category: ONCOLOGY | ||||||
| 05/12/2021 | Helsinn Healthcare SA | VALCHLOR (Drug) | Royalty or License | Cash or cash equivalent | $1,238.02 | General |
| Category: ONCOLOGY | ||||||
| 01/15/2021 | Helsinn Healthcare SA | VALCHLOR (Drug) | Royalty or License | Cash or cash equivalent | $933.58 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2020 | Helsinn Healthcare SA | VALCHLOR (Drug) | Royalty or License | Cash or cash equivalent | $664.91 | General |
| Category: ONCOLOGY | ||||||
| 11/11/2020 | Helsinn Healthcare SA | VALCHLOR (Drug) | Royalty or License | Cash or cash equivalent | $480.37 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| MS 700568-0002 | Merck KGaA | $3,500 | 2 |
About Dr. Philip Schein, M.D
Dr. Philip Schein, M.D is a Medical Oncology healthcare provider based in Bryn Mawr, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/17/2012. The National Provider Identifier (NPI) number assigned to this provider is 1124399571.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Philip Schein, M.D has received a total of $443,059 in payments from pharmaceutical and medical device companies, with $5,986 received in 2024. These payments were reported across 161 transactions from 7 companies. The most common payment nature is "Consulting Fee" ($348,475).
Ad
Practice Information
- Specialty Medical Oncology
- Location Bryn Mawr, PA
- Active Since 01/17/2012
- Last Updated 01/17/2012
- Taxonomy Code 207RX0202X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1124399571
Products in Payments
- VALCHLOR (Drug) $63,118
- XELJANZ (Drug) $53,476
- Bavencio (Biological) $37,994
- Mavenclad (Biological) $27,286
- Cladribine (Biological) $3,500
- Mavenclad (Drug) $2,189
- AFREZZA (Drug) $1,913
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.